Inflammation plays a pivotal role in various pathological conditions, necessitating the exploration of natural compounds for their anti-inflammatory properties. Medicinal plants have long been recognized as valuable sources of bioactive molecules with therapeutic potential. This study aimed to investigate the anti-inflammatory activity of selected medicinal plants using THP1 cell lines, a widely utilized model for studying inflammatory responses. The experimental setup involved the exposure of THP1 cells to extracts or isolated compounds derived from medicinal plants Ruelliatuberosa known for their traditional use in treating inflammatory disorders. Cellular responses were evaluated through assays targeting key inflammatory markers such as cytokine production, NF-κB activation, and expression of inflammatory mediators. Preliminary results demonstrated significant attenuation of inflammatory responses in THP1 cells following treatment with the tested plant extracts or compounds. Suppression of pro-inflammatory cytokines such as interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumour necrosis factor-alpha (TNF-α) was observed, indicating a potential mechanism of action for the observed anti-inflammatory effects. Furthermore, the downregulation of NF-κB signalling pathway components suggested the involvement of this pathway in mediating the anti-inflammatory activity of the tested plant-derived agents. These findings underscore the therapeutic potential of the medicinal plant Ruelliatuberosa in modulating inflammatory responses, offering promising avenues for the development of novel anti-inflammatory agents. Further investigations into the molecular mechanisms underlying their effects and the identification of specific bioactive compounds are warranted to fully exploit their therapeutic potential and facilitate their integration into clinical practice.